Moh Tadayyon
Co-founder Apeikon Therapeutics
Moh has over two decades of experience spanning discovery, pre-clinical and early development, clinical translation and scientific commercial strategy. Moh is a co-founder of Apeikon Therapeutics, a spinout from King’s College London that is developing a novel drug-delivery technology for treatment of solid tumours, including glioblastoma. Moh’s early career was in metabolic disease research where he led multiple programs that delivered several clinical candidates including the now marketed antidiabetic linagliptin.
Seminars
Thursday 3rd December 2026
Evidence – Building Integrated Development Strategies to Improve Development Time-lines & Reduce Late-Stage Risks
2:40 pm
- Reducing late-stage risk by integrating decision making across biology, pharmacology and regulatory functions
- Aligning model selection, biomarker strategy, PK/PD understanding, formulation and regulatory planning earlier in development
- Updating ‘traditional’ organisation structures to improve communication between discovery, translational, and clinical and regulatory functions
Thursday 3rd December 2026
Insight Exchange – Building an End-to-End Development Strategy That Delivers Better Decisions
3:20 pm
- Where do development programmes most commonly break down between discovery, translational, clinical, and external partners?
- How early should CROs, translational scientists, and pharmacology teams be involved in model selection decisions?
- What distinguishes a strategic partner from a service provider when generating decision-grade data?
- How can organisations balance speed, cost, scientific rigour, and translational confidence throughout development?
- Audience Q&As
